A Phase 1/2 Study CB-103 With or Without Venetoclax in Patients With NOTCH ACC
Status:
Not yet recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to treat patients with NOTCH active advanced adenoid cystic
carcinoma (ACC) tumors with a combination or two different oral medications to slow tumor
growth and improve survival outcomes.
The names of the study drugs involved in this study are:
- CB-103 (an oral NOTCH pathway inhibitor)
- Venetoclax (a BCL-2 inhibitor)
- Lenvatinib (a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase
inhibitor (TKI))
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Glenn J. Hanna
Collaborators:
Adenoid Cystic Carcinoma Research Foundation Cellestia Biotech AG